ClinicalTrials.gg
CompletedNCT05913479HYDRAGYNEUpdated Feb 19, 2026

Evaluation of the Efficacy and Safety of Mucogye® Gel as a Moisturizer

An interventional study of Mucogyne Gel in Vaginal Dryness, sponsored by Biocodex. Completed at 4 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Biocodex · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The aim of this post-Market Clinical Follow-up (PMCF) study for a class IIb medical device is to confirm th efficacy and safety of Mucogyne Gel as a moisturizer in women with vaginal dryness irrespective of the cause; when used in accordance with its approved labelling.

02

Conditions studied

  • Vaginal Dryness
03

In context

Lead sponsor

Biocodex is the lead sponsor of 19 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Women with the following conditions:

  • ≥ 18 years of age at inclusion with vaginal dryness, irrespective of the cause (which may or may not be accompanied by irritation of the vulva, discomfort, or itchiness).
  • Having a Vaginal Health Index Score (VHIS) \<15 associated to pain and/or dyspareunia feeling.
  • Subject agrees to not use any lubricant, local estrogens, or other vaginal product during the study.
  • Subject agrees to not modify their intimate hygiene products.
  • Able to understand and sign the form for study enrolment.
  • Subject able to comply with study requirements, as defined in the protocol.
  • Subject affiliated to a health social security system.

Exclusion criteria

Exclusion Criteria:

Women with the following conditions:

  • General:

    • Pregnancy (subject of must not be pregnant and must agree to avoid pregnancy during the study by using an effective method from at least one month before D0 (V0) and throughout the duration of the study).
    • Participating at the same time in another interventional trial within the four previous weeks and during the study period, being in an exclusion period for a previous study.
    • Deprived of freedom by administrative or legal decision or under guardianship.
    • Subject in a social or sanitary establishment.
    • Subject suspected to be non-compliant according to the investigator's judgment.
    • Subject in an emergency situation.
  • Linked to subject's status:

    • Known to one of MUCOGYNE® Gel components.
    • Subject with a known vaginal pathology (clinical diagnosis only) other than vaginal dryness/atrophy.
  • Linked to previous or ongoing treatments:

    • Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk.
    • Subject suffering from systemic diseases and/or using concurrent therapy that may interfere with the evaluation of the study results.
    • Subject undergoing a topical treatment on the test area or a systemic treatment: during the 2 previous weeks and during the study; retinoids and/or immunosuppressors during the 1,5 previous months and during the study; subject having started or changed her oral contraceptive or any other hormonal treatment during the one previous month.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Mucogyne treatment

    3 planned visits for each eligible patient: * Screening/Baseline visit: V0 at Day 0. Patient receive a box of Mucogyne Gel. * Phone call: V1 phone call at Day 10 ± 3 * End-of-study visit: V2 at Day 35 ± 3

    Device: Mucogyne Gel

Interventions

  • DeviceMucogyne Gel

    At inclusion visit (V0), the Investigator will ask the subject to apply MUCOGYNE® Gel as described in the Instructions For Use, i.e., internally, one application 2 to 3 times a week until symptoms improve during 5 weeks (D35 +/- 3)

06

What researchers measure

Primary outcomes

  1. Assessment of the efficacy of MUCOGYNE® Gel intra vaginal applications on subjects' vaginal dryness irrespective of the cause over a 35-day period of use.

    Primary efficacy criterion: Clinical scoring, by the investigator, of the Vaginal Health Index Score (VHIS), including evaluation of elasticity, fluid volume, pH, epithelial integrity, and moisture.

    Time frame: Day 0 to Day 35 +/- 3

Secondary outcomes

  1. Assessment of the local performance of MUCOGYNE® Gel in reducing vulva irritation

    Secondary efficacy criteria \- Auto-evaluation, by the subjects, of pain and/or dyspareunia on Visual Analogical Scales (VAS) from 0 to 10

    Time frame: Day 0 to Day 35 +/- 3

  2. Assessment of the local performance of MUCOGYNE® Gel in reducing vulvo-vaginal dryness

    Secondary efficacy criteria \- Clinical scoring of vulvo-vaginal dryness by the Investigator on a Visual Analogical Scale from 0 to 10

    Time frame: Day 0 to Day 35 +/- 3

  3. Assessment by investigator of changes in patient's clinical status

    Secondary efficacy criteria \- Completion of the CGI-I (Clinical Global Impressions-Improvement) by the Investigator.

    Time frame: Day 0 to Day 35 +/- 3

  4. Assessment of changes in patient's clinical status

    Secondary efficacy criteria \- Completion of the Patients' Global Impression of Change (PGIC) Scale to assess the changes perceived by the patient following the treatment taken.

    Time frame: Day 0 to Day 35 +/- 3

  5. Assessment of the patient's satisfaction

    Secondary efficacy criteria \- Completion of the intra vaginal treatment satisfaction questionnaire (Likert questionnaire) to assess the level of satisfaction of the treatment on the vaginal symptoms.

    Time frame: Day 0 to Day 35 +/- 3

  6. Assessment of the patient's sexual function

    Secondary efficacy criteria \- Completion of the self-reported FSFI (Female Sexual Function Index) to investigate sexual function (for women having sexual relations).

    Time frame: Day 0 to Day 35 +/- 3

07

Study locations

4 sites
  • Dr Paul Lefevre's medical office
    Caen, 14000, France
  • Dr Thierry KELLER's medical office
    Colmar, 68000, France
  • Dr Christiane ARMAND's medical office
    Écully, 69130, France
  • Sihame MOKHBAT's office
    Paris, 75018, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Jan 2026, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2023
First posted
Jun 22, 2023
StartActual
Oct 10, 2023
Primary completionActual
Jan 2, 2026
CompletionActual
Jan 2, 2026
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05913479
Lead sponsor
Biocodex
Collaborators
Voisin Consulting Life Science (VCLS)
Responsible party
Sponsor
First posted
Jun 22, 2023
Start date
Oct 10, 2023
Primary completion
Jan 2, 2026
Completion
Jan 2, 2026
Last update
Feb 19, 2026

Study contacts

Oana BERNARD, MD
study director · Chief Scientific officer

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion